<DOC>
	<DOCNO>NCT02349542</DOCNO>
	<brief_summary>The purpose study evaluate serum level ( pharmacokinetics ) bupivacaine series patient undergo simultaneous bilateral total knee arthroplasty use standardize periarticular injection contain free bupivacaine liposomal bupivacaine .</brief_summary>
	<brief_title>Liposomal Bupivacaine Simultaneous Bilateral Total Knee Arthroplasty</brief_title>
	<detailed_description>Total knee arthroplasty ( TKA ) commonly perform successful surgical procedure show dramatically decrease pain improve patient 's function quality life . Certain patient may present significant pain limitation due pain knee base age , health degree deformity may candidate bilateral simultaneous total knee arthroplasty . The safety efficacy simultaneous bilateral total knee arthroplasty well documented literature . Inadequate postoperative pain control follow TKA one great source patient dissatisfaction follow total knee arthroplasty . Traditionally , manage parenteral oral narcotic . Recently , number study demonstrate efficacy multimodal analgesia follow variety surgical procedure . These multimodal regimen vary consist number medication include non-steroidal anti-inflammatory , anti-epileptics , peripheral nerve block among others . These multimodal regimen associate reduction use opioid analgesic , lead few opioid-associated adverse event . One new modality introduce market liposomal bupivacaine ( Exparel ) . Liposomal bupivacaine lipid encapsulate bupivacaine allows depo administration medication soft tissue surgical procedure . The lipid engineer slowly release approximately 72 hour time period , result slow release free bupivacaine soft tissue surgical site . This propose advantage long duration analgesia compare standard bupivacaine injection . Liposomal bupivacaine apply periarticular injection conclusion TKAs aid post-operative pain control . Due lipid encapsulation bupivacaine , 3 % free bupivacaine release tissue initial infiltration , remainder release slowly approximately 72 hour time frame . To cover , gap period , liposomal bupivacaine mixed standard bupivacaine allow immediate analgesic effect . A potential risk , although low , concern bupivacaine toxicity . Toxicity bupivacaine associate central nervous system issue ( seizure ) cardiac toxicity . Toxicity dose dependent recommend level exceed 400mg/24 hr period . With use bupivacaine surgical site , theoretical risk , administer intra-vascularly , bupivacaine toxicity . To date , study evaluate safety liposomal bupivacaine use simultaneous bilateral total knee arthroplasty . The use liposomal bupivacaine FDA approve infiltration one vial one surgical site . Other specialty evaluate use one vial liposomal bupivacaine two surgical site ( breast augmentation ) one surgery without adverse event . To date , approximately 8-10 patient investigator 's institution undergone simultaneous bilateral total knee arthroplasty use liposomal bupivacaine without known adverse event . A recent study publish Bramlett ( 2012 ) use 2 vial ( 532mg ) one knee evaluate efficacy . There change patient 's vitals sign cardiac event patient receive liposomal bupivacaine high dose . In addition , study Bergese look dose 600mg liposomal bupivacaine Phase 2 safety study find adverse cardiac event . The purpose study evaluate serum level ( pharmacokinetics ) bupivacaine series patient undergo simultaneous bilateral total knee arthroplasty use standardize periarticular injection contain free bupivacaine liposomal bupivacaine .</detailed_description>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>Patients deem appropriate candidate simultaneous bilateral total knee arthroplasty . Patients receive general anesthesia Understands local language willing able follow requirement protocol Understands informed consent sign institutional review board/ independent ethic committee ( IRB/IEC ) approve informed consent form Patients le 18 year age Allergy bupivacaine Allergy epinephrine Patients medically clear undergo bilateral total knee replacement surgery , Patientreported liver impairment ( per investigator discretion ) Patientreported renal impairment ( per investigator discretion ) Patients receive spinal anesthesia Females pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Liposomal Bupivacaine</keyword>
	<keyword>Simultaneous Bilateral Total Knee Arthroplasty</keyword>
	<keyword>Safety</keyword>
</DOC>